Medical cannabis use in Canada: Vapourization and modes of delivery

Harm Reduction Journal

Volumn 13, Issue 1, 2016, Pages

  Shiplo, Samantha ^a   Asbridge, Mark ^b   Leatherdale, Scott T ^a   Hammond, David ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Medical cannabis; Policy; Population health

Indexed keywords

MEDICAL CANNABIS;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CANADA; CHRONIC PAIN; CONVENIENCE SAMPLE; CROSS-SECTIONAL STUDY; DEPRESSION; ELECTRONIC CIGARETTE; EPILEPSY; FEMALE; FIBROMYALGIA; GLAUCOMA; HARM REDUCTION; HEALTH BELIEF; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; RESPIRATORY TRACT DISEASE; SPINAL CORD INJURY; VAPORIZATION; VAPORIZER; VOMITING; ANALYSIS OF VARIANCE; CANNABIS SMOKING; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PERCEPTION; UTILIZATION; VAPING; VOLATILIZATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; CROSS-SECTIONAL STUDIES; ELECTRONIC CIGARETTES; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; MEDICAL MARIJUANA; NEBULIZERS AND VAPORIZERS; PATIENT SATISFACTION; PERCEPTION; VAPING; VOLATILIZATION;

EID: 84995777919     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/s12954-016-0119-9     Document Type: Article

References (34)

1. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-27.
2. Canada H. Information for health care professionals cannabis (marihuana, marijuana) and the cannabinoids. 2013. Retrieved from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf. Accessed 5 Sept 2014.
3. Canada H. Canadian alcohol and drug use monitoring survey. 2012. http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2012/summary-sommaire-eng.php. Accessed 23 Nov 2014.
4. Canada H. Canadian alcohol and drug use monitoring survey. 2014. http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2012/summary-sommaire-eng.php. Accessed 23 Nov 2014.
5. Canada H. Marihuana medical access program (MMAR) statistics 2013. 2014. http://www.hc-sc.gc.ca/dhp-mps/marihuana/stat/index-eng.php. Accessed 2 Feb 2015.
6. Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of cannabis and cannabinoids-an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45(3):199-210.
7. Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduction J. 2005;2:18.
8. Ware MA, Tawfik VL. Safety issues concerning the medical use of cannabis and cannabinoids. Pain Res Manag. 2005;10(Supplement A):31A-7A.
9. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain. 2003;102(1-2):211-6.
10. Hathaway AD. Cannabis users' informal rules for managing stigma and risk. Deviant Behav. 2004;25(6):559-77.
11. Ogborne AC, Smart RG, Adlaf EM. Self-reported medical use of marijuana: a survey of the general population. Can Med Assoc J. 2000;162(12):1685-6.
12. Bottorff JL, Bissell LJ, Balneaves LG, Oliffe JL, Capler NR, Buxton J. Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study. Harm Reduct J. 2013;10 (2). DOI: 10.1186/1477-7517-10-2.
13. Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduction J. 2007;4:11.
14. Gates P, Jaffe A, Copeland J. Cannabis smoking and respiratory health: consideration of the literature. Respirology. 2014;19(5):655-62.
15. Fischer B, Imtiaz S, Rudzinski K & Rehm J. Crude estimates of cannabis-attributable mortality and morbidity in Canada-implications for public health focused intervention priorities. Journal of Public Health (Oxford, England). 2015; Advanced online publication.
16. Hashibe M, Morgenstern H, Cui Y, Tashkin DP, Zhang Z, Cozen W, Mack TM, Greenland S. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1829-34.
17. O'Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in California (2001-2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduction J. 2007;4:16.
18. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther. 2007;82(5):572-8.
19. Van Dam NT, Earleywine M. Pulmonary function in cannabis users: support for a clinical trial of the vaporizer. Int J Drug Policy. 2010;21(6):511-3.
20. Pomahacova B, Van Der Kooy F, Verpoorte R. Cannabis smoke condensate III: the cannabinoid content of vaporised cannabis sativa cannabinoid content of vaporised cannabis sativa. Inhal Toxicol. 2009;21(13):1108-12.
21. Gieringer D, St Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther. 2004;4(1):7-27.
22. Malouff JM, Rooke SE, Copeland J. Experiences of marijuana-vaporizer users. Subst Abus. 2014;35(2):127-8.
23. Czoli C, Reid J, Rynard V, Hammond D. E-cigarettes in Canada-tobacco use in Canada: patterns and trends, 2015 edition, special supplement. 2015. http://www.tobaccoreport.ca/2015/TobaccoUseinCanada_2015_EcigaretteSupplement.pdf. Accessed 8 July 2015.
24. Czoli CD, Hammond D, White CM. Electronic cigarettes in Canada: prevalence of use and perceptions among youth and young adults. Can J Public Health. 2014;105(2):e97-e102.
25. Thrasher JF, Quah AC, Dominick G, Borland R, Driezen P, Awang R, Omar M, Hosking W, Sirirassamee B, Boado M. Using cognitive interviewing and behavioral coding to determine measurement equivalence across linguistic and cultural groups: an example from the International Tobacco Control Policy Evaluation Project. Field Methods. 2011;23(4):439-460.
26. The American Association for Public Opinion Research (AAPOR). Standard definitions: final dispositions of case codes and outcome rates for surveys 8th edition. 2015. https://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions2015_8theditionwithchanges_April2015_logo.pdf. Accessed 8 July 2015.
27. Lucas P. It can't hurt to ask; a patient-centered quality of service assessment of health Canada's medical cannabis policy and program. Harm Reduction J. 2012;9(2):b23.
28. Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs. 2011;43(2):128-35.
29. Belle-Isle L, Hathaway A. Barriers to access to medical cannabis for Canadians living with HIV/AIDS. AIDS Care. 2007;19(4):500-6.
30. Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci. 2003;30(3):201-5.
31. Hazekamp A, Ruhaak R, Zuurman L, Van Gerven J, Verpoorte R. Evaluation of a vaporizing device (volcano®) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci. 2006;95(6):1308-17.
32. Earleywine M, Van Dam NT. Case studies in cannabis vaporization. Addict Res Theory. 2010;18(3):243-9.
33. Mitchell IV. Vaporizer legalization. Can Med Assoc J. 2014;186(12):937-0062.
34. The Huffington Post. Medical marijuana insurance coverage awarded to Jonathan Zaid, Waterloo student. 2015. http://www.huffingtonpost.ca/2015/03/16/medical-marijuana-insurance-sun-life-jonathan-zaid_n_6881578.html. Accessed 3 July 2015.